Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Genes
|
May 5, 2021
Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with <i>EGFR</i> Exon 20 Insertion Mutations
Giulio Metro, Sara Baglivo, Guido Bellezza, et al.
Anti-Cancer Drugs
|
May 31, 2018
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma
Roberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 18, 2025
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)
Francesco Facchinetti, Andrea Camerini, Chiara Bennati, et al.
Cancer Immunology, Immunotherapy : CII
|
February 3, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study
Michele Maffezzoli, Alessio Signori, Alessandro Acunzo, et al.
Tumori
|
May 4, 2026
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world study
Alessandro Leonetti, Vanessa Callegari, Fabiana Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 15, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
Alessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.
Journal of Hematology & Oncology
|
January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
Alessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2023
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer
Marco Tagliamento, Alessandra Gennari, Matteo Lambertini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
Alessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
Journal for Immunotherapy of Cancer
|
April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Alessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Genes
|
May 5, 2021
Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with <i>EGFR</i> Exon 20 Insertion Mutations
Giulio Metro, Sara Baglivo, Guido Bellezza, et al.
Anti-Cancer Drugs
|
May 31, 2018
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma
Roberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 18, 2025
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)
Francesco Facchinetti, Andrea Camerini, Chiara Bennati, et al.
Cancer Immunology, Immunotherapy : CII
|
February 3, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study
Michele Maffezzoli, Alessio Signori, Alessandro Acunzo, et al.
Tumori
|
May 4, 2026
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world study
Alessandro Leonetti, Vanessa Callegari, Fabiana Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 15, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
Alessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.
Journal of Hematology & Oncology
|
January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
Alessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2023
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer
Marco Tagliamento, Alessandra Gennari, Matteo Lambertini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
Alessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
Journal for Immunotherapy of Cancer
|
April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Alessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
Page
of 5